Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.59 |
| ▸ | DNM2 | P50570 | 4/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11278962 | 0.98 | DNM2 (0.58) | TLR8DNM2HRH3NUDT1HRH4 | |
| SCHEMBL14619916 | 0.95 | TLR8 (0.66) | TLR8DNM2HRH3NUDT1HRH4 | |
| SCHEMBL16139312 | 0.88 | TLR8 (0.51) | TLR8DNM2HRH3NUDT1HRH4 | |
| SCHEMBL14907960 | 0.81 | HRH3 (0.68) | TLR8HRH3NUDT1HRH4STK17A | |
| SCHEMBL11286031 | 0.81 | NUDT1 (0.66) | TLR8DNM2HRH3NUDT1HRH4 | |
| SCHEMBL1401613 | 0.81 | DNM2 (0.78) | TLR8DNM2HRH3NUDT1HRH4 | |
| SCHEMBL12330669 | 0.81 | HRH3 (0.55) | TLR8DNM2HRH3NUDT1HRH4 | |
| SCHEMBL32678680 | 0.81 | HSD17B10 (0.50) | TLR8HRH3NUDT1HRH4KMT2A | |
| SCHEMBL32678687 | 0.81 | HSD17B10 (0.50) | TLR8HRH3NUDT1HRH4KMT2A | |
| SCHEMBL1519145 | 0.80 | TLR8 (0.42) | TLR8HRH3NUDT1HRH4HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112574177-B | Pyrimidine derivatives and application thereof in preparing antitumor drugs | 陕西师范大学 | 2023-01-31 | — | — | CN | disclosed |
| CN-112574177-A | Pyrimidine derivatives and application thereof in preparing antitumor drugs | 陕西师范大学 | 2021-03-30 | — | — | CN | disclosed |
| EP-2311825-B1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| US-20120277258-A1 | Chemical Compounds | LEO OSPREY LIMITED (JE) | 2012-11-01 | — | — | US | disclosed |
| US-8114885-B2 | Pazopanib hydrochloride and synthesis, chemical intermediates, and dosage forms thereof; anticancer; colon cancer, breast cancer | GLAXOSMITHKLINE LLC (US) | 2012-02-14 | — | — | US | disclosed |
| EP-2311825-A1 | Pyrimidineamines as angiogenesis modulators | GlaxoSmithKline LLC (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7858626-B2 | Pyrimidineamines as angiogenesis modulators | GLAXOSMITHKLINE LLC (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100105712-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-04-29 | — | — | US | disclosed |
| EP-1343782-B1 | PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS | SMITHKLINE BEECHAM CORP (US) | 2009-05-06 | — | — | EP | disclosed |
| US-7459455-B2 | Pyrimidine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| US-20070270427-A1 | CHEMICAL COMPOUNDS | NOVARTIS AG (CH) | 2007-11-22 | — | — | US | disclosed |
| US-7262203-B2 | Pyrimidineamines as angiogenesis modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | disclosed |
| US-7105530-B2 | inhibitors of vascular endothelial growth factor receptor-2 kinase; pazopanib and salts; for proliferative retinopathy; anticancer | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-20050085637-A1 | Antiproliferative agents; angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-04-21 | — | — | US | disclosed |
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | disclosed |
| EP-1472233-A1 | PYRIMIDINE COMPOUNDS | SmithKline Beecham Corporation (US) | 2004-11-03 | — | — | EP | disclosed |
| EP-1343782-A1 | PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2003066601-A1 | PYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-14 | — | — | WO | disclosed |
| WO-2002059110-A1 | PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS | GLAXO GROUP LIMITED (GB) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | TYMS, TYMP, DPYD | TLR8 3337/4885DNM2 1711/4885HRH3 294/4885 |
| US-20070015756-A1 | Chemical compounds | KDR, FLT4, FLT1 | TLR8 3246/4885DNM2 948/4885HRH3 853/4885 |
| US-20100105712-A1 | CHEMICAL COMPOUNDS | KDR, FLT4, FLT1 | TLR8 3246/4885DNM2 948/4885HRH3 853/4885 |
| US-20120277258-A1 | Chemical Compounds | KDR, FLT4, FLT1 | TLR8 3246/4885DNM2 948/4885HRH3 853/4885 |
| US-20070270427-A1 | CHEMICAL COMPOUNDS | KDR, FLT4, FLT1 | TLR8 3246/4885DNM2 948/4885HRH3 853/4885 |
| US-20050085637-A1 | Antiproliferative agents; angiogenesis inhibitors | TIE1, TEK, KDR | TLR8 3173/4885DNM2 207/4885HRH3 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.